PPA Intervention

Phase 3Small molecule

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

PPA Intervention is one of 60 small molecule programs targeting Intracerebral Hemorrhage. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intracerebral HemorrhageNot yet recruiting

Ischemic StrokeRecruiting

Intracerebral HemorrhagePhase 3

Not yet recruiting

Ischemic StrokePhase 3

Recruiting

Competition

Competitive Landscape

116 competitors in Ischemic Stroke

#DrugCompanyPhaseTrials

Tnkase

Roche

Phase 3

17 2

Ozempic

Novo Nordisk

Phase 3

3 3

Reminyl

WWim Janssens

Phase 3

1 4

Atorvastatin Calcium

Merck & Co.

Phase 3

1 5

Tegoprazan

SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Phase 3

1 6

SGLT-2 Inhibitors

Novo Nordisk

Phase 3

1 7

PPA Intervention

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Phase 3

1 8

Proamatine

Takeda

Preclinical

2 9

Levaquin

WWim Janssens

Preclinical

3 10

Tylenol

KKenvue Brands

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ischemic stroke1 trial

Reduction of Edema With a Specialized Cocktail for Ultra-early Management in Ischemic Stroke

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT06863571·68 enrolled

Intracerebral Hemorrhage1 trial

Reduction of Edema With a Specialized Cocktail for Ultra-early Management in Intracerebral Hemorrhage

Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT06863558·58 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for PPA Intervention. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PPA Intervention compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PPA Intervention. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Second Affiliated Hospital, School of Medicine, Zhejiang University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSecond Affiliated Hospital, School of Medicine, Zhejiang University

PPA Intervention

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ischemic stroke1 trial

Intracerebral Hemorrhage1 trial

References

Drug Info

Quick Facts

Related News